Engineered immune cells take on tough bone cancer in first human test
NCT ID NCT07227571
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new type of immune cell therapy called FH-FOLR1 ST CAR T-cells for people with advanced osteosarcoma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells, and infusing them back into the patient. The study aims to find the safest dose and check for side effects in up to 30 participants aged 1 to 75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FH-FOLR1 ST CAR T-cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced osteosarcoma that has not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 30 participants, so it is too soon to know if the therapy works. There are risks of serious side effects from the CAR T-cells and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Desperate hope: single patient gets custom RNA therapy for returning bone cancer
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws
- Experimental drug shows promise for Tough-to-Treat bone cancers
- New hope for young cancer patients: experimental drug targets recurrent tumors